Company news

CAMP4 Therapeutics Corporation news in 2026

CAMP4 Therapeutics Corporation's news releases, calls and decks from 2026, newest first.

View company

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 17, 2026

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

November 5, 2026

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

October 27, 2026

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

September 10, 2026

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

September 8, 2026

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 13, 2026

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

August 4, 2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

July 27, 2026

CalAmp Expands Remote Monitoring Support for Modbus-Enabled Specialty Equipment

July 16, 2026

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

May 14, 2026

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

May 7, 2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

April 28, 2026

Calamos Brings Award-Winning Autocallable Income ETF Strategy to Global Investors with Launch of World's First Autocallable UCITS ETF

April 27, 2026

CAMP4 Appoints Michael MacLean to its Board of Directors

March 24, 2026

CAMP4 Appoints Michael MacLean to its Board of Directors

March 24, 2026

CAMP4 to Participate in Upcoming Investor Conferences

March 6, 2026

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

March 5, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Decks in 2026